NL-OMON37643已完成不适用
A Three Part Study Evaluating the Pharmacokinetics of Intravenous (IV) Danoprevir (DNV)/Oral Low Dose Ritonavir (RTV), a Drug-Drug Interaction Study Between IV DNV/Oral Low Dose RTV and Oral Cyclosporine, and the Absolute Bioavailability of IV DNV as Compared to DNV Tablets Together With Oral Low Dose RTV in Healthy Adult Volunteers - DNV DDI with Ritonavir and Cyclosporine and Absolute Bioavailability
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male or female subjects
- •18-55 yrs, inclusive
- •BMI: 18.0-32.0 kg/m2, inclusive
- •Weight: * 50.0 kg
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
进行中（未招募）
1 期
A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary AngioedemaHereditary AngioedemaMedDRA version: 12.1Level: LLTClassification code 10019860Term: Hereditary angioedemaEUCTR2010-022716-39-DEDyax Corp.22
招募中
3 期
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Through 11 Years of AgeCystic Fibrosis2024-513754-29-00Vertex Pharmaceuticals Inc.15
进行中（未招募）
1 期
Evaluation of VX-445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 YearsCystic FibrosisEUCTR2018-001695-38-GBVertex Pharmaceuticals Incorporated56
进行中（未招募）
1 期
Evaluation of VX-445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 YearsCystic FibrosisEUCTR2018-001695-38-IEVertex Pharmaceuticals Incorporated56
进行中（未招募）
1 期
A clinical study with a Factor VIIa (Recombinant) to evaluate its efficacy, its safety and its behaviour in human blood in patients with Hemophilia A or B with inhibitors to factor VIII or IXCongenital haemophilia A or B patients with inhitors to Factor VIII or Factor IXMedDRA version: 17.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 17.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2013-004779-11-ROrEVO Biologics, Inc.27